Marcin Czerwinski/LinkedIn;
Radoslaw Kaczmarek/LinkedIn
Mar 28, 2026, 17:01
Marcin Czerwinski: Neutralizing Anti-AAV Antibodies in Hemophilia B Gene Therapy
Marcin Czerwinski, Professor at Hirszfeld Institute of Immunology and Experimental Therapy, shared a post on LinkedIn about a recent article by Radoslaw Kaczmarek, adding:
“Radoslaw (Radek) Kaczmarek just wrote a great commentary about neutralizing anti-AAV antibodies (NAbs) in hemophilia B therapy that can block transduction, thereby abolishing efficacy.
It seems that this is not the case…”
Title: Hemophilia B gene therapy: a NAb-solute barrier overcome by AAV5
Author: Radoslaw Kaczmarek
Read the Full Article on RPTH Journal
Stay updated with Hemostasis Today.
-
Jun 28, 2026, 10:34Heghine Khachatryan: Menarche as the First ‘Bleeding Challenge’
-
Jun 28, 2026, 10:13Mohammed Alharbi: Assessing Warfarin Management and Anticoagulation Quality in Older Populations
-
Jun 28, 2026, 10:03Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
-
Jun 28, 2026, 09:55Utkarsh Pandey: Japan Approves Wayrilz for ITP Patients
-
Jun 28, 2026, 09:41Sung-mok Jung: How Environmental Drivers Influence SFTS Occurrence
-
Jun 28, 2026, 05:17Burcu Tunakan: Turning Collaboration into Better Outcomes for People with Hemophilia
-
Jun 28, 2026, 05:08Kathrine Kaspersen: The Power of Voluntary Plasma Donation
-
Jun 28, 2026, 04:55Sana Helani: Challenging Common Assumptions in Anemia Management
-
Jun 28, 2026, 04:55Samwel Mikaye: The Collapse of Coagulation Control in Disseminated Intravascular Coagulation